Literature DB >> 3768871

Human autopsy tissue concentrations of mitoxantrone.

D J Stewart, R M Green, N Z Mikhael, V Montpetit, M Thibault, J A Maroun.   

Abstract

A sensitive high-performance liquid chromatography method was used to measure mitoxantrone in autopsy tissue samples of 11 patients who had received the drug iv 10-272 days antemortem. Mitoxantrone was readily detectable in tissues from all patients. Tissue concentrations were proportional to lifetime cumulative dose of mitoxantrone, and decreased very slowly with time. The thyroid and the liver had the highest mitoxantrone concentrations, followed by the heart. These high cardiac concentrations of mitoxantrone could be partially responsible for the occasional case of cardiotoxicity seen with mitoxantrone. The brain had the lowest mitoxantrone concentrations. Organ mitoxantrone concentrations did not conform to a flow-limited model. Tumor mitoxantrone concentrations varied quite markedly from one site to another in the same patient. Tumors generally had lower mitoxantrone concentrations than did surrounding normal tissues. Mitoxantrone concentrations were consistently highest in intrahepatic tumors and lowest in intracerebral tumors. It is unclear whether the low concentrations in brain tumors were due to a partially intact blood-brain barrier or to the fact that most brain tumors had been irradiated prior to mitoxantrone administration. Further studies are warranted to more fully explore the relationship between human tissue mitoxantrone concentrations and efficacy and toxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3768871

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  27 in total

1.  Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data.

Authors:  A Boiardi; A Salmaggi; A Pozzi; G Broggi; A Silvani
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

2.  Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.

Authors:  A Boiardi; M Eoli; A Salmaggi; E Lamperti; A Botturi; G Broggi; L Bissola; G Finocchiaro; A Silvani
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

Review 3.  Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.

Authors:  L R Wiseman; C M Spencer
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

4.  Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.

Authors:  Amerigo Boiardi; Mirco Bartolomei; Antonio Silvani; Marica Eoli; Andrea Salmaggi; Elena Lamperti; Ida Milanesi; Andrea Botturi; Paola Rocca; Lisa Bodei; Giovanni Broggi; Giovanni Paganelli
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

Review 5.  Mitoxantrone: a review of its use in multiple sclerosis.

Authors:  Lesley J Scott; David P Figgitt
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 8.  Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.

Authors:  C J Dunn; K L Goa
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

9.  Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide.

Authors:  D J Stewart; D Grewaal; M D Redmond; N Z Mikhael; V A Montpetit; R Goel; R M Green
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Human autopsy-tissue distribution of menogaril and its metabolites.

Authors:  D J Stewart; D Grewaal; R M Green; R Goel; N Mikhael; V A Montpetit; D Redmond; R Earhart
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.